drugset / Trial / NCT02522650

A Crossover Pilot Study of the Effect of Amiloride on Proteinuria

NCT02522650

Phase 4 Unknown 30 enrolled Georgetown University
RandomizedCrossoverOpen-labelTreatment

Summary

This cross-over study is designed to test the hypothesis that amiloride will reduce urinary protein excretion and protect the kidney from rapid progression in proteinuric kidney disease.

Timeline

Start
2013-07
Primary completion
2021-10
Completion
2021-10

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Amiloride Small molecule 5 mg
Comparator triamterene Small molecule 50 mg

Indications